Nicotine / THR - Statements from Experts

Safer nicotine wiki Tobacco Harm Reduction
Revision as of 10:36, 10 January 2022 by Skip (talk | contribs) (Stuart Griffiths)
Jump to navigation Jump to search

Scientists, Professors, Medical Professionals, Tobacco Control and Public Health Leaders, along with Lawmakers are speaking out in support of adult use of Tobacco Harm Reduction (THR) products to help people quit smoking and to prevent relapse.



Argentina

Dr. Diego Verrastro

File:Argentina - Dr. Diego Joaquin Verrastro.jpg


Milton Klun

Pharmacist Universidad Nacional del Sur. Argentina



Australia

Ron Borland PhD

Quote Source / Bio and Photo

File:Australia - Ron Borland.jpg


Wayne Hall

Quote Source / Bio and Photo

File:Australia - Wayne Hall.jpg


Dr. Alex Wodak AM

File:Australia - Alex Wodak.jpg


Colin Mendelsohn, MB BS

File:Australia - Colin Mendelsohn.jpg


Judith Watt

Former Executive Director, NCD Alliance Former Director, Quit Victoria,


Dr Kevin Murphy


Senator Hollie Hughes


Fiona Patten MP



Austria

Bernhard-Michael Mayer, PhD

Professor of Pharmacology and Toxicology Institute of Pharmaceutical Sciences Karl-Franzens-Universität Graz Austria


Ernest Groman, MD

Associate Professor Nicotine Institute & Medical University of Vienna Austria


Belgium

Frank Baeyens, PhD

File:Frank Baeyens.jpg


Karolien Adriaens, PhD



Canada

Ian Irvine, PhD

Quote / Bio / Photo

File:Canada - Ian Irvine.jpg



David Sweanor, JD

Quote Source / Bio and Photo

File:Canada - David Sweanor.jpg


Chris Lalonde, PhD


Amelia Howard, Sociologist


Mark Tyndall MD ScD FRCPC

Professor, School of Population and Public Health University of British Columbia Canada


Dr John Oyston


Martin Juneau MPs, MD, FRCP(C)

Director, Prevention and Cardiac Rehabilitation Montreal Heart Institute Full Clinical Professor of Medicine Faculty of Medicine University of Montreal, Canada


Michael Chaiton


Clifford Garfield Mahood, O.C.

Founding Executive Director (1976-2012) Non-Smokers’ Rights Association Toronto Canada


Patrick Fafard, PhD

Full Professor Centre for Health Law, Policy, and Ethics Graduate School of Public and International Affairs University of Ottawa


Kellie Ann Forbes BScN

Here


Chili

Hernán Prat, MD, PhD

Professor at the University of Chile. Former Director of the Cardiovascular Department of the Clinical Hospital of the University of Chile. Former president of the Chilean Society of Hypertension. Chile



Colombia

Hugo Caballero Durán, MD

Former president of the Colombian Society of Pneumology. Former Clinical Scientific Director of Marly Clinic. Director of the Pneumology and Respiratory Therapy Service, Marly Clinic Bogotá, Colombia



Czech Republic

Eva Králíková, MD

Professor Institute of Hygiene and Epidemiology Centre for Tobacco-Dependence First Faculty of Medicine and General Hospital Charles University Prague Czech Republic


Pavel Bém MD

Member of the Global Commission on Drug Policy Head of the Clinical Department, Adictology Clinic, Charles University Former Mayor of Prague Member of The National Drug Commission Office of the Government of the Czech Republic



Ecuador

Enrique Teran, MD, PhD

Professor College of Health Sciences - Universidad San Francisco de Quito. Ecuadorian Academy of Medicine Academy of Science of Ecuador Ecuador


Francisco E. Urrestra. MD.

Medical Director Hospital Clinica Metropolitana. Ibarra.


César Paz y Miño, MD, PhD

Director, Centro de Investigacion Genética y Genómica and Specialist in Genetics and Human Molecular Biology Universidad UTE Quito, Ecuador



England

John Britton, MD

Quote Source / Bio and Photo

File:UK - John Britton.jpg


Sharon Cox, PhD

File:UK - Sharon Cox.jpg


Lynne Dawkins, PhD

File:UK - Lynne Dawkins.jpg
  • Disclosures: I have provided consultancy for the pharmaceutical industry relating to the development of smoking cessation products. I have no conflicts with respect to the tobacco or e-cigarette industry.


Peter Hajek, PhD

Quote Source / Bio and Photo

File:UK - Peter Hajek.jpg


Martin Jarvis ODE, PhD

Quote Source / Bio and Photo

File:UK - Martin Jarvis.jpg


Caitlin Notley, PhD

File:UK - Caitlin Notley.jpg


David Nutt DM, FRCP, FRCPsych, FSB, FMedSci

Quote Source / Bio and Photo / Follow on Twitter

File:UK - David Nutt.jpg


Louise Ross

File:UK - Louise Ross.jpg


Lion Shahab, PhD CPsychol AFBPsS

File:UK - Lion Shahab.jpg
  • Disclosures: LS has received a research grant, honoraria for talks, consultancy and travel expenses to attend meetings and workshops from pharmaceutical companies that make smoking cessation products (Pfizer; Johnson & Johnson). He has never received any funding or other monetary benefits from the tobacco or e-cigarette industry.


John Newton, FRCP FFPH FRSPH

Quote Source / Bio


Rosemary Leonard, MBE, MA, MB, BChir, MRCGP, DRCOG

Quote Source / Bio / Follow on Twitter


Sir Norman Lamb

Graphics Source / Follow on Twitter


David Halpern

  • We should deliberately seek to make e-cigs widely available, and to use regulation not to ban them but to improve their quality and reliability.
  • Quote Source


Jim McManus, OCDS, FFPH

Jim McManus, Director of Public Health, Hertfordshire: How and why I changed my mind on e-cigarettes,

Dr. Sudhanshu Patwardhan

Snus Forum Interview

Sanjay Agrawal, MD, MBChB


Robert West, PhD

Professor Emeritus in Health Psychology, University College London


Marcus Munafò, PhD

Professor of Biological Psychology and MRC Investigator MRC Integrative Epidemiology Unit School of Psychological Science University of Bristol United Kingdom


Prof Paul Aveyard


Dr Leonie Brose


Olivia M Maynard, PhD

Senior Lecturer, School of Psychological Science Bristol Population Health Science Institute MRC Integrative Epidemiology Unit Bristol, United Kingdom


Martin Dockrell


Benjamin Human

Source of name

Deborah Arnott

Over at ASH, however, Arnott summarily dismisses such fears. “There are people in the public health community who are obsessed by e-cigarettes,” she says. “This idea that it renormalises smoking is absolute bullshit.” Furthermore, she insists, “There is no evidence so far that it is a gateway into smoking for young people.” ASH’s concern, she says, “is quite the reverse—that because there is so much bad publicity about them, people’s understanding about the relative risk of smoking and e-cigarettes is being undermined. The risk is that smokers who could potentially use these as an alternative to smoking are being discouraged, and that’s not a good thing.” For Arnott, the concept of harm reduction boils down to a simple proposition: “Do you want the tobacco industry to carry on making cigarettes which are highly addictive and kill when used as intended, or do you want them to move to a product which is much nearer licensed nicotine replacement therapy and is unlikely to kill anyone?”

Dr Russell Thorpe

Quote source

Dr Kathryn Scott

  • Quote Source
  • chief executive at Yorkshire Cancer Research
  • "Easy and reliable access to vaping products will give more people in Yorkshire the best chance of quitting for good.”



Stuart Griffiths

  • Quote Source
  • Director of research, services and policy at Yorkshire Cancer Research
  • " “When it comes to helping people quit for good, being able to offer vaping products is essential. They are an incredibly effective aid in helping people give up cigarettes.”


France

Jacques Le Houezec, PhD


File:France - Jacques Le Houezec.jpg


Professor Bertrand Dautzenberg


File:France - Bertrand Dautzenberg.jpg


Philippe Arvers, MD, PhD

Tobaccologist ans addictologist Université Grenoble Alpes France


Marion Adler, PhD

Smoking Cessation Specialist Hôpital Antoine Béclère Clamart France


Germany

Peter Liese MEP

Tweet about Peter

Frank Sitta

tweet about Frank

PROFESSOR HEINO STÖVER

PROFESSOR HEINO STÖVER and here

Prof. Dirk Ziebolz


Dr Ingo Schröder


Greece

Konstantinos Farsalinos, MD, MPH

Quote Source / Bio and Photo / Follow on Twitter

File:Greece - Konstantinos Farsalinos.jpg


Iceland

G. Karl Snæ MD


India

Dr Nimesh Desai

File:India - Nimesh Desai.jpg


Kiran Melkote, MBBS, MS

Associate Consultant Dept. of Orthopaedics Fortis Memorial Research Institute, New Delhi India


Aparajeet Kar, MD

Consultant Pulmonology and Critical Care Sir H.N Reliance Foundation Hospital Mumbai India


Rohan Sequeira, MD, PhD

Professor of Internal Medicine Specialist in Non-Invasive Cardiology, Diabetes, Endocrinology and Obesity Management Jaslok Hospital and Research Centre Mumbai India


Ireland

Dr Garrett McGovern

Bio Article and Quote

Italy

Riccardo Polosa

Quote Source / Bio


Umberto Tirelli MD

Professor Director, Cancer Center Clinica Mede Sacile


Pietro Fiocchi

  • Follow on Twitter
  • Tweet with info
  • Quote: I would like to emphasize the help deriving from vaping devices in gradually eliminating the phenomenon of smoking, and therefore reducing the risk to the health of the smoker as much as possible, not forgetting the social cost, especially in terms of loss of human life caused by tobacco, which could be contained with a targeted damage mitigation strategy ".


Japan

Naohito Yamaguchi, MD

Chief of Research Division, Saiseikai Research Institute of Health Care and Welfare Former Professor of Public Health, School of Medicine, Tokyo Women's Medical University


Lithuania

Morgana Danielė

video on twitter

Malaysia

Dr Steven Chow

Quote Source / Bio and Photo

File:Malaysia - Steven Chow.jpg


Dr Arifin Fii


Shamsul Bahri Mohd Tamrin, PhD

Professor of Occupational Safety and Health/Ergonomics Department of Environmental and Occupational Health University Putra Malaysia Shamsul Bahri Mohd Tamrin, PhD


Mexico

Roberto A Sussman, PhD

Department of Gravitation and Field Theories Institute for Nuclear Research, National Autonomous University of Mexico, ICNUNAM Representing Pro-Vapeo Mexico AC Mexico


Christian Heinrich Henonin MD

MIPH International Public Health. Medical professor, researcher and health consultant Mexico


Morocco

Imane Kendili M.D.

Psychiatre - Addictologue Professeure affiliée à l'UM6P Cheffe de service Psychiatrie-Addictologie Clinique Andalouss Vice-Présidente du Centre Africain de Recherche en Santé Morocco


New Zealand

Ruth Bonita, MPH, PhD, MD (hon) and Robert Beaglehole, MD, DSc

File:NZ - Bonita and Beaglehole.jpg


Marewa Glover


Deborah Hart LLB


Natalie Walker, PhD

Associate Professor of Population Health and Director of the Centre for Addiction Research, National Institute for Health Innovation, Faculty of Medical and Health Sciences, University of Auckland


Eliana Golberstein Rubashkyn, B.Sc. Pharm, B. Chem

Consultant, advisor in health policy and toxicology. National University of Colombia


George Laking, MD, PhD

Chair, End Smoking New Zealand


Yolande Jeffares


Dr Murray Laugesen

  • Follow on Twitter
  • “…inhaling mist from the e-cigarette is rated several orders of magnitude (100 to 1000 times) less dangerous than smoking tobacco cigarettes.”
  • Quote Source


PM Jacinda Ardern


Nigeria

Clive Bates

Quote Source / Bio and Photo / Follow on Twitter

File:Nigeria - Clive Bates.jpg


Norway

Karl E Lund, PhD

File:Norway - Karl Lund.jpg


Pakistan

Dr Ashar Ahmed

Source for name and quote

Philippines

Dr. Fernando Fernandez

Quote Source / Bio and Photo

File:Phillipines - Fernando Fernandez.jpg


Ron Christian G. Sison, MLS(ASCPi), MPH

Assistant Professor Lead Convenor Harm Reduction Alliance of the Philippines Manila Philippines


Arleen R. Reyes, DMD, ICD, ICCDE

Past President, Philippine Dental Association Chairman, Commission on Dental Education Asia -Pacific Dental Federation Philippines


Poland

Andrzej Sobczak, PhD

Professor Head of Department of General and Inorganic Chemistry Faculty of Pharmaceutical Sciences in Sosnowiec Medical University of Silesia Katowice Poland


Scotland

Dr. Ehsan Latif


Prof Linda Bauld, OBE


South Korea

Young-bum Park, PhD

Professor Department of Economics Hansung University South Korea


Spain

Fernando Fernández Bueno, MD

Oncological surgeon at the Hospital Central de la Defensa Gómez Ulla Professor at the University of Alcalá de Henares Madrid Spain


Josep María Ramón Torrell, MD, PhD.

Professor of Epidemiology and Public Health University of Barcelona Head of Clinical Prevention Research Group Bellvitge Biomedical Research Institut Head of Tobacco Prevention Service Bellvitge Hospital Barcelona, Spain


José David García Muñiz, MD, PhD

Clinical Pharmacology and Internal Medicine Clinical Trials Coordinator, Principal Investigator University Hospital of Ceuta Spain


Francisco Garcia Sierra, MD.

Head of the Nephrology Service University Hospital of Ceuta Spain


Angel González Ureña, PhD

Emeritus Professor of Physical Chemistry. Complutense University of Madrid


Maria del Mar Sangüesa Jareño, MD

Intensive Care Specialist University Hospital of Ceuta, Spain


Antonio Sierra, MD, PhD

Professor of Preventive Medicine and Public Health at the University of La Laguna. Former Dean of the Faculty of Medicine of the University of La Laguna Former General Director of Public Health of the Government of the Canary Islands


Carmen Escrig, PhD

Genetics and Cell Biology Autonomous University of Madrid Spain


Manuel Linares Abad, PhD


Miguel de la Guardia PhD

Professor of Analytical Chemistry University of Valencia Spain


José Mª García Basterrechea, MD

Associate Professor of Medicine University of Murcia Former head, Addiction and Dual Pathology Unit Reina Sofía Hospital. Spain.


Singapore

Andrew John da Roza

Psychotherapist - Addictions Promises Health Care Pte. Ltd. Singapore


Tan Kok Kuan, MD

Medical Director Dr Tan Medical Center Novena Medical Center Singapore


Sweden

Anders Milton MD, PhD

Quote Source / Bio and Photo

File:Sweden - Anders Milton.jpg


Lars Ramström PhD

Quote Source / Bio and Photo

File:Sweden - Lars Ramstrom.jpg


KARL FAGERSTRÖM PhD


Switzerland

Tikki Elka Pang, PhD

Former Director, Research Policy & Cooperation, WHO, Geneva Switzerland


Jean-François Etter, PhD

Professor of public health Institute of Global Health, Faculty of Medicine University of Geneva


Dr. Moira Gilchrist

Include a disclosure about PMI

Tunisia

Fares Mili MD-CTTS- NCTTP

Quote Source: / Bio and Photo

File:Tunisia - Fares Mili.jpg


United States

Kenneth Warner, PhD


File:Kenneth Warner2.jpg



  • Quote Source
  • Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • Evidence from six completely different sources demonstrates that vaping is increasing smoking cessation.
      • 1. Randomized controlled trials. The Cochrane Review, the gold standard of scientific credibility, says there is “moderate certainty evidence” that vaping increases smoking cessation more effectively than do nicotine replacement therapy products.
      • 2. Population studies find e-cigarettes increasing smoking cessation, especially when people use ecigarettes frequently.
      • 3. As e-cigarette sales rise, cigarette sales fall. Econometric studies confirm the two products are substitutes.
      • 4. Other studies have found that policies intended to decrease youth vaping have increased youth smoking. Another study found that a tax on e-cigarettes in Minnesota increased adult smoking and decreased smoking cessation.
      • 5. Multiple simulation analyses have concluded that the potential benefit of vaping for adult smoking cessation substantially outweighs any risk that vaping might increase youth smoking.
      • 6. Swedish men’s substituting snus, a smokeless tobacco product, for cigarettes demonstrates the potential for lower-risk products to dramatically reduce tobacco-produced diseases.
    • Tragically, public health organizations that focus exclusively on the potential risks of vaping for young people – risks that, frankly, have been grossly exaggerated – are likely to be damaging the health of the public.
    • Kenneth Warner, PhD
    • Avedis Donabedian Distinguished University Professor Emeritus of Public Health,
    • Dean Emeritus of Public Health
    • University of Michigan


Steven Schroeder

File:Steven Schroeder2.jpg


Mitch Zeller, JD

File:Mitch Zeller2.jpg


Dr. Scott Gottlieb


File:USA - Scott Gottlieb.jpg


Alex Azar, JD


File:USA - Alex Azar.jpg


Dr. Jerome Adams


File:USA - Jerome Adams.jpg


David Abrams

File:David Abrams.jpg
  • 1-David Abrams good quotes from David and others
  • 2-Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • WHO of all Institutions should base its policies and recommendations on the best and strongest scientific evidence available. The WHO can do better at saving the lives of over a billion smokers by updating its science and by correcting the massive misinformation that all forms of nicotine and tobacco -products are equally deadly and thus smokers should quit or die rather than reduce their harms dramatically by using dramatically less harmful modes of nicotine delivery.
    • The WHO misinformation is not science at its best, it is tantamount to embracing propaganda. Propaganda that conflates all tobacco and nicotine products as being equally harmful. This is unacceptable from such an august and respected body as WHO, it is antithetical to the core values of WHO – of social justice, eradication of preventable chronic diseases where combusted (smoked ) tobacco and some forms of smokeless tobacco but not nicotine itself is the primary driver of chronic diseases, death and untold suffering.
    • David B Abrams PhD.
    • Professor of Social and Behavioral Sciences
    • New York University School of Global Public Health


Tom Miller


Iowa Attorney General
Iowa Attorney General



Scott Ballin, JD

  • Photo: Monique Calello / The News Leader
  • Bio: Has served as chairman of the Coalition on Smoking or Health (the precursor to the Campaign for Tobacco-Free Kids); vice president of the American Heart Association; steering committee of the Alliance for Health Economic and Agriculture Development (AHEAD); advisor to the Food and Drug Law Institute’s tobacco conferences; advisor to the University of Virginia's Morven Dialogues on tobacco, nicotine and harm reduction.
  • Statement: Most smokers want to quit and if we can provide those smokers with science based, consumer acceptable lower risk products we could fundamentally alter the current marketplace and save hundreds of thousands of premature deaths.
  • Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • This year approximately 8 million people will die prematurely from smoking. I am deeply disappointed with what can only be described as an ongoing 'dark ages' approach to tobacco control. While many traditional forms of tobacco control remain useful and effective, little has been done by the WHO and many other mainstream public health organizations to acknowledge and think about how regulation, research, technology and innovation can be collectively harnessed to give the billion addicted cigarette smokers viable science based lower risk products. Science and 'safe-haven' engagement and debate continues to be displaced with polarized thinking that often is more focused on getting media attention than actually finding workable win-win solutions for the good of society.
    • Scott D. Ballin, JD
    • Health Policy Consultant
    • Former Vice President and Legislative Counsel, American Heart Association
    • Former Chairman of the Coalition on Smoking OR Health (AHA, ASCS. ALA)
    • Advisor to the University of Virginia, Institute for and Engagement and Negotiation (The Morven Dialogues)


Kenneth Michael Cummings PhD, MPH

  • 1-Source: If you have somebody pulling their chemo bag and they are going to sneak a cigarette out behind the cancer center, which we see, it’s pretty sad. It ain’t a choice. It’s a true addiction. There are alternative nicotine delivery products that don’t have to send you to your local cancer center,”
  • 2-Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • The status-quo is unacceptable – 8-million deaths from cigarettes just this year, more next and the year after that. WHO’s ideologic, non-science based position on lower risk nicotine products as substitutes for deadly cigarettes is costing lives and protecting the profits of the very companies they wish to put out of business. Please update your tobacco control playbook, lives are stake.”
    • K. Michael Cummings, PhD, MPH - Bio and Photo
    • Professor, Medical University of South Carolina, USA


Ovide Pomerleau, PHD


Dorothy K. Hatsukami, PhD


Kenneth A. Perkins, PhD


Harry A. Lando, PhD


Nancy A. Rigotti, MD


David J. K. Balfour, DSc


Dr. Michael Madden

Dr. Michael Madden: Clearing the air about youth vaping

Scott Leischow, PhD


Caryn Lerman, PhD


Gary E. Swan, PhD


Clifford E. Douglas, J.D

  • Follow on Twitter
  • 1-Statement:
    • All nicotine-containing products fall along a continuum of risk – with combustible tobacco products like cigarettes on one end representing the most dangerous form of nicotine delivery, and on the other end medicinal nicotine products. For the smoker, quitting all nicotine and tobacco use is the surest way to reduce risk, but for those who want or need to continue using nicotine, switching to a noncombustible source of nicotine will significantly reduce their risk compared to continued smoking.
  • 2-Comments on vaping and tobacco harm reduction from expert stakeholders
    • The WHO blithely, and quite wrongly, claims that switching from smoking cigarettes, by far the leading preventable cause of premature death and disability, to far less harmful e-cigarettes—which they cleverly but unscientifically imply may be deadly—is not quitting,
    • Clifford E. Douglas, J.D.
    • Director, Tobacco Research Network
    • Adjunct Professor, Department of Health Management and Policy
    • University of Michigan School of Public Health
  • Bio and photo:
    • In 1988 he served as the associate director of the National Coalition on Smoking or Health, where he worked for its founding director, Matt Myers (who later became the president of the Campaign for Tobacco-Free Kids); He served as an attorney and advisor in the state attorney general actions that resulted in the Master Settlement Agreement; Worked as a policy advocate, lawyer and consultant on behalf of Americans for Nonsmokers’ Rights and the Public Health Law Center; Served as the American Cancer Society’s Vice President for Tobacco Control and as the founding Director of ACS’s Center for Tobacco Control; He is the Director, University of Michigan Tobacco Research Network and Adjunct Professor, University of Michigan School of Public Health.


Allan Erickson

No Photo found. Source #1 Bio: Former Vice President for Public Education and Tobacco Control, American Cancer Society; staff director, Latin American Coordinating Committee for Tobacco Control. National Tobacco Reform Initiative (NTRI) Coordinator Statement / Quotes: I know how totally horrible tobacco is for a human being, and what it does to you. But I think things are moving in the direction of harm reduction. I think a lot of people have hidden their heads in the sand. They are just so totally opposed to e-cigarettes, it drives them nuts. I think there is a whole range of new products that are coming up that could potentially be better and better and better—less harmful.

Abigail S. Friedman, Ph.D.

  • Follow on Twitter
  • Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • A myriad of studies link e-cigarette price increases and access-restrictions to greater smoking rates. Findings from biochemical analyses suggest that such regulations are likely to be harmful on net: vaping nicotine appears to produce substantially lower levels of key toxicants than smoking cigarettes; and, adverse respiratory and cardiovascular outcomes as well as biomarkers for major carcinogens generally fall when smokers switch to nicotine e-cigarettes. Thus, for smokers who do not want to quit tobacco or who want to quit but have been unsuccessful in their cessation attempts, substituting towards electronic nicotine delivery systems offers a means to reduce their risk of tobacco-related illness. The public health community and World Health Organization have a moral obligation to clearly communicate these facts to smokers and their families, and to advocate for policies that reflect tobacco products’ relative risks.”
    • Abigail S. Friedman, Ph.D. - Bio and Photo
    • Assistant Professor,
    • Department of Health Policy and Management
    • Yale School of Public Health


Jonathan Foulds PhD

  • Follow on Twitter
  • Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • Over a billion people smoke tobacco. All smokers should be informed that many sources of nicotine are far less harmful than cigarettes. Keeping people ignorant of this fact denies the basic human right to accurate information and impairs their ability to make informed choices that affect their health. Nicotine in its most harmful and addictive form—the cigarette—is typically cheap, available everywhere, to take for as long as you like, and in many parts of the world (including the USA) comes with minimum information on health risks. It is time for regulation of all nicotine-delivery products to provide access inversely proportional to harmfulness (the opposite of the current situation). [Foulds & Kozlowski, 2007]
    • Jonathan Foulds PhD - Bio and Photo
    • Professor of Public Health Sciences & Psychiatry
    • Penn State University, College of Medicine, United States

Jonathan Foulds PhD

Alex Liber


Dr. Cheryl Healton

Founding President and CEO of American Legacy Foundation (created from MSA Funds, now known as the Truth Initiative); Dean of School of Global Public Health and Professor of Public Health Policy and Management, NYU School of Global Public Health; Founding chair of the Public Health Practice Council of the Association of Schools of Public Health; Serves on the National Board of Public Health Examiners, the Betty Ford Institute, Lung Cancer Alliance, Board of Directors at the Association of Schools and Programs of Public Health, and the Board of Directors at HealthRight International. Tobacco Harm Reduction Quote: E-cigarette Summit 2021 We treat addiction to combustible tobacco differently than addiction to other products with respect to harm reduction approaches. We are spending way too much time on infighting and too little time on finding common ground to massively reduce combustible tobacco use and ending the false equivalency between products. Smoking remains a worldwide tragedy causing a billion lives at stake in this century alone. Lower risk products exist to help those unable or unwilling to quit. We have abandoned our harm reduction approach in public health when it comes to saving smokers. Retirement from American Legacy (now Truth)

Bethea A Kleykamp, MA, PhD

  • Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • As I write these words, thousands upon thousands of people are losing their lives because of tobacco smoking. Each of these lives had a story—a story cut short because health authorities including the WHO are not using scientific and regulatory resources to make harm reduction products and information fully available to the public. Let us finally come to our senses and stop these unnecessary deaths by embracing the science of harm reduction.”
    • Bethea A Kleykamp, - Bio and Photo
    • Research Associate Professor,
    • University of Rochester Medical Center
      • COI: I currently have no conflicts of interest with respect to tobacco, vaping or pharmaceutical industries. From May 2014 to September 2018, I provided harm reduction consulting services to an e-cigarette company (NJOY) and a tobacco company (RJ Reynolds) through my work at Pinney Associates.


Lynn Kozlowski


Ethan A Nadelmann

  • Follow on Twitter
  • Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • It took WHO all too many years to embrace “harm reduction” thinking and policies vis a vis consumers of illicit drugs but it eventually did. Hundreds of thousands, possibly millions of lives, could have been saved if WHO had acted earlier to transcend the political forces and counterproductive ideologies and rhetoric that drove the war on drugs and its insistence on punitive abstinence-only policies.
    • Yet now we see WHO repeating very similar mistakes as it resists and dismisses the technological innovations in tobacco and nicotine products that could radically reduce associated harms to both consumers and society at large. The organization’s leaders need to open their eyes and summon the courage to follow the science, not the politics. Failure to do so may ultimately result in the emergence of an international tobacco/nicotine prohibition regime with all the failures, costs and counter-productive consequences of the failed global drug prohibition regime.
    • Ethan A Nadelmann - Bio and Photo
    • Founder & Former Executive Director (2000-2017)
    • Drug Policy Alliance
    • New York and International


Raymond S. Niaura, PhD


John Seffrin, MD, PhD

Photo Source #1 and Source #2 Bio: Former CEO of the American Cancer Society and ACS Cancer Action Network. Served on the White House Advisory Group on Prevention, Health Promotion, and Integrative and Public Health, as well as the Advisory Committee to the Director of the Centers for Disease Control and Prevention. He also served on the National Cancer Policy Board of the Institute of Medicine and the National Cancer Legislation Advisory Committee. He is a past president of the International Union Against Cancer. He helped to create the National Center for Tobacco-Free Kids (now the Campaign for Tobacco-Free Kids) Source #1 and Source #2 Statement: Technologies/alternatives exist today that can help people quit smoking or at least reduce significantly their consumption of burned tobacco, which is what kills them. After fighting the tobacco epidemic for over 5 decades, we now have proven harm reduction methods to help us avoid a carnage in otherwise preventable deaths.

Michael Siegel

Visiting Professor, Department of Public Health and Community Medicine Tufts University School of Medicine Boston


Paul Newhouse

Quote source "It [nicotine] seems very safe even in nonsmokers. In our studies we find it actually reduces blood pressure chronically. And there were no addiction or withdrawal problems, and nobody started smoking cigarettes. The risk of addiction to nicotine alone is virtually nil."

Robin Mermelstein, Ph.D.

Distinguished Professor, Liberal Arts and Sciences Psychology Department Director, Institute for Health Research and Policy Co-Director, Center for Clinical and Translational Science University of Illinois at Chicago


Charles A. Gardner, PhD


Arielle Selya, PhD

(need to find a quote)

(Add disclosure about now working @Pinney)

Thomas J. Glynn, PhD

Adjunct Lecturer Prevention Research Center School of Medicine, Stanford University Formerly, Associate Director, Cancer Control Science Program, U.S. National Cancer Institute, and Director, Cancer Science and Trends, American Cancer Society


Matthew Wayne Johnson, Ph.D.

Quote / Bio and Photo

File:Matthew W. Johnson.jpg


Veronique de Rugy, PhD


File:USA - Veronique de Rugy2.jpg


Cheryl K. Olson, Sc.D.

  • Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • Too few of my colleagues in public health research know people who smoke; they become abstractions to us. Existing smoking cessation aids have been available for many years; evidence suggests they don’t help most smokers. Let’s treat smokers like fellow human beings and provide them with a range of options they actually want and can live with (pun intended).
    • Cheryl K. Olson, Sc.D. - Bio and Photo
    • San Carlos, California
    • Behavioral research consultant,
    • Previously on Harvard Medical School psychiatry faculty


Michael F. Pesko, PhD

  • Follow on Twitter
  • Source: Comments on vaping and tobacco harm reduction from expert stakeholders
    • The evidence base is growing that when you regulate e-cigarettes so they are harder to purchase and/or less appealing to use, there is more combustible tobacco product use across all populations. WHO should acknowledge that e-cigarettes (and snus) are safer products, and advocate regulating proportionate to risk, in order to improve population health.
    • Michael F. Pesko, PhD - Bio and Photo
    • Associate Professor
    • Department of Economics
    • Andrew Young School of Policy Studies
    • Georgia State University


Daniel Wikler, Ph.D.


Michael Fiore

"In just today, we are going to lose 20 of our residents. Twenty individuals in Wisconsin are going to die prematurely of a disease directly caused by their smoking, on average, robbing them of 10 to 15 years of life." " Many adults don't want children exposed to secondhand smoke. Vaping is, without a question, less dangerous than cigarette smoking."

Thomas Brandon, PhD, United States

Moffitt Cancer Center



Earlier this year, the findings from a major clinical trial, published in the New England Journal of Medicine, showed that e-cigarettes were almost twice as effective as the nicotine patch for producing one year of smoking cessation. These findings added to those of other, smaller studies previously published.

“This could be a game-changer for lots of people,” says Thomas Brandon, Ph.D., director of Moffitt’s Tobacco Research and Intervention Program and chair of the Department of Health Outcomes and Behavior. “It means that for smokers who have not been able to quit by using the available medications, vaping might be worth a try. But it is important to completely switch from smoking to vaping to get the most health benefits.”

Thomas Brandon, PhD, is the Director of the Tobacco Research and Intervention Program and Chair of the Department of Health Outcomes and Behavior at Moffitt Cancer Center. He is also Professor of Psychology and Oncologic Sciences at the University of South Florida

SEE: Tweet w/graphic

Neal Benowitz


Sally Satel


Peter Killeen PhD

If e–cigs displace cigarettes and help people quit other tobacco products—and they already have been shown to do so—how do we justify discouraging their use?

Sheila Vakharia, PhD

Tweet thread

Carl V. Phillips, MPP, PhD

Bio 1 and Bio 2 Quote Source "Three months of additional smoking poses a greater risk to someone’s health, on average, than a lifetime of using a low-risk alternative."

Dr. Brad Rodu


Helen Redmond


Carrie Wade, PhD

Include disclosure about JUUL

Bill Godshall

Quote Source / Graphic Source / Photo Source

File:USA - Bill Godshall.jpg


Robert Sklaroff

Source of name - need to research for a quote

Suzanne M. Colby, PhD


  • Professor of Psychiatry and Human Behavior, Center for Alcohol & Addiction Studies, Warren Alpert School of Medicine at Brown University
  • 2019-2020 President, Society for Research on Nicotine and Tobacco
  • Source of name, need to find their own quote



Vaughan Rees, PhD


File:USA - Vaughan Rees.jpg



Stephen F. Gambescia, PhD


File:USA - Stephen Gambescia.jpg


Joel Nitzkin, MD


File:USA - Joel Nitzkin.jpg


Jasjit S Ahluwalia, MD, MPH, MS


File:USA - Jasjit S Ahluwalia.jpg


Jason Osborne


File:USA - Jason Osborne.jpg



Jeffrey Brandes


File:USA - Jeffrey Brandes2.jpg


Venezuela

Natasha A. de Herrera, PhD

Clinical Psychology Centro Medico Docente la Trinidad Psychiatric Unit Smoking Cessation Clinic Caracas Venezuela


Statements by Multiple Parties

2021: One hundred specialists call for WHO to change its hostile stance on tobacco harm reduction - new letter to FCTC delegates published


2021: Reappraising Choice in Addiction: Novel Conceptualizations and Treatments for Tobacco Use Disorder


2021: 75 Tobacco Control experts ask CDC to change the name of EVALI


2019: Testimony for New York Senate hearing on vaping safety - Clive Bates and David Sweanor


2018: Letter from seventy-two specialists in nicotine science, policy and practice


Suggestions to add to this page

expert reaction to Department of Health press release ‘e-cigarettes could be prescribed on the NHS in world first’

E-cig Summit UK 2021 speakers


A New International Commission of Experts Finds the Global Fight Against Smoking Has Stalled

CRUCIAL STEP IN TOBACCO HARM REDUCTION

Canada

Sec. Azar (need to find original source, might be a youtube video) VTA Graphic and Hawaii Graphic


expert reaction to WHO report on nicotine and tobacco products

Michael Erikson

Ending Cigarette Use By Adults In A Generation Is Possible

Letter with names to research

More names to research for positive statements

Jaron Hoani King

Comments on vaping and tobacco harm reduction from expert stakeholders

More names on this doc

World No Tobacco Day: Here's why WHO’s approach to tobacco cessation needs an overhaul

The Truth Initiative, too, once embraced harm reduction. Its former board chairman, Tom Miller, Iowa’s long-serving attorney general, still argues that e-cigarettes are a “means to saving millions of lives.” Cheryl Healton, its former CEO, and David Abrams, formerly executive director of the Schroeder National Institute of Tobacco Research and Policy Studies, which is housed at the Truth Initiative, are harm-reduction advocates. So is Steven Schroeder, for whom the institute is named. Found here


72 Statements to WHO


M.O.V.E.


Dr. Derek Yach

  • “We’ve been very clear that we support provisions that children should never vape or smoke. However, our main objective is to help adult smokers quit by making cessation aids accessible and to support adult smokers switching to approved harm reduction products. These include snus, e-cigarettes, heated-tobacco products and nicotine pouches,” says Yach. “In the long term, tackling cessation together with harm reduction is the only way to bring smoking rates down relatively soon. If today’s adult smokers quit or switch, even into their fifties or sixties, they will see improvements in their quality of life.”

Quotes

Retrieved from ‘https://safernicotine.wiki/mediawiki/index.php?title=Nicotine_/_THR_-_Statements_from_Experts&oldid=23456’